At issue in this settlement are 12 products — NCHS's Advate, Benefix, Eloctate, Feiba NF, Helixate FS, Humate-P, Kogenate FS, Mononine, NovoSeven RT, Recombinate, Rixubis, and Stimate. The federal and state civil settlement resolves allegations that from January of 2009 through November of 2014, NCHS recruited certain individuals whose relatives required one or more the above-listed blood-factor products. NCHS then allegedly provided those individuals illegal remuneration to induce them or their relatives to purchase the drugs from NCHS, in violation of the Anti-Kickback Statute. An investigation revealed that NCHS recruited parents whose children have hemophilia as marketers — paying the parents a commission each time they purchased their children's medication through NCHS. These medications can cost tens of thousands of dollars per dose.